Adaptive Biotechnologies Corporation (ADPT) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Adaptive Biotechnologies Corporation (ADPT) slipped -0.70% to $28.17, trading at 86% of its 52-week range ($12 – $30.74). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
In matched multi-center cohorts, Telo Genomics is expanding comparative evaluation of blood-based TELO-MRD against Adaptive Biotechnologies' clonoSEQ next-generation sequencing MRD testing.Vancouver, British Columbia--(N
For questions about this article or underlying research, email help@trefis.com.
Fred Alger Management, an investment management company, released its third-quarter 2026 investor letter for “Alger Small Cap Growth Fund”. The letter can be downloaded here. U.S. equities rose modestly in Q3 2026, with
Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ADPT stock is a buy.
For questions about this article or underlying research, email help@trefis.com.
Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
Tempus AI (TEM) stock has lost 17.3% over the past month, while the S&P 500 gained 0.6%. The company still grew sales 22% in its latest quarter, but the risk worth your attention lies with the few drugmakers that license
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +54.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ADPT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ADPT. Explore sector supply chains on /butterfly.
Across 188 tracked Health Care securities in the Roarable RQD universe, Adaptive Biotechnologies Corporation (ADPT) ranks #150 by composite RQD confidence (51/100, grade D) and #164 by equity capitalization ($4.50B). Within this direct 5-issuer industry benchmark cohort, ADPT leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. ADPT currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADPT
ACTIVE
Adaptive Biotechnologies Corporation | D | 51/100 | — | 74.2% | -12.5% | -0.70% | $4.50B | Benchmark Subject |
| IOVA Iovance Biotherapeutics Inc. | D | 48/100 | — | 34.3% | -35.0% | -35.45% | $4.33B | /iova-vs-adpt → |
| CRSP CRISPR Therapeutics AG | D | 44/100 | — | — | -30.6% | +0.28% | $5.25B | /crsp-vs-adpt → |
| SRRK Scholar Rock Holding Corporation | D- | 42/100 | — | — | -35.0% | +2.15% | $5.38B | /srrk-vs-adpt → |
| CGON CG Oncology Inc. | D- | 42/100 | — | — | -20.8% | -0.77% | $5.63B | /cgon-vs-adpt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adaptive Biotechnologies Corporation (ADPT) reported GAAP revenue of $277.0M (+54.8% vs. FY2024 revenue of $179.0M , and +62.7% cumulative change since FY2023) , GAAP net income of -$59.5M, operating cash flow of -$46.0M, and free cash flow of -$48.9M (+50.5% YoY). On the balance sheet, ADPT closed FY2025 with $512.7M in total assets against $126.6M in total debt (Altman Z-Score: 6.32, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $277.0M | -$59.5M | -$46.0M | -$48.9M | $512.7M | $126.6M |
| FY2024 (FY) | 2024-12-31 | $179.0M | -$159.5M | -$95.2M | -$98.9M | $539.4M | $132.4M |
| FY2023 (FY) | 2023-12-31 | $170.3M | -$225.3M | -$156.3M | -$164.0M | $2.47B | $578.6M |
As of 2026-11-01, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $28.17 (-0.70% 1D, market cap $4.50B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, ADPT ranks #150 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADPT carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -12.5%. By comparison, IOVA (Iovance Biotherapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $4.33B) and CRSP (CRISPR Therapeutics AG) posts a D grade (44/100 RQD, P/E N/A, ROIC -30.6%, cap $5.25B). Among the 5-stock peer group, ADPT leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per ADPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478320), Adaptive Biotechnologies Corporation generated $277.0M in revenue (+54.8% YoY), -$59.5M in net income, and -$48.9M in free cash flow against $512.7M in total assets and $126.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ADPT last traded at $28.17 (-0.70% on volume of 2,588,942 shares), positioning the stock +6.62% above its 50-day simple moving average ($26.42) and +43.29% above its 200-day simple moving average ($19.66). Across its 52-week range of $12.00 to $30.74, ADPT sits at the 86.3% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.4% ($24.68 to $31.66).
Why ADPT Stock slipped -0.70% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.